# A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

> **NCT07332000** · PHASE2 · RECRUITING · sponsor: **Candel Therapeutics, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Prostate Cancer Patients Treated by Radiotherapy
- Prostate Cancer (Adenocarcinoma)

## Interventions

- **BIOLOGICAL:** aglatimagene besadenovec + valacyclovir
- **RADIATION:** External Beam Radiation Therapy (EBRT)

## Key facts

- **NCT ID:** NCT07332000
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07332000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07332000, "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07332000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*